Overview

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M

Status:
Enrolling by invitation

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

Evaluate the efficacy and safety of Anlotinib combined with Icotinib as the second-line treatment in stage IIIb-IV NSCLC patients with sensitive EGFR and T790M mutations.

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Osimertinib